BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

Core Points - BioNexus Gene Lab Corp. has regained full compliance with Nasdaq Listing Rule 5550(a)(2), confirming a minimum bid price of $1.00 per share [1] - This milestone signifies the company's commitment to growth and compliance, allowing it to pursue innovation, capital market engagement, and international expansion [2] - The CEO emphasized that this achievement reflects the company's strategic alignment and financial resilience, positioning it for future growth opportunities [3] Corporate Strategy - The company is implementing a multi-pronged strategy focused on reinforcing corporate governance, enhancing internal controls, and preparing for strategic partnerships and capital raising [4] - New independent board members have been appointed, and a dedicated internal audit function has been established to support long-term value creation initiatives [4] - The continued Nasdaq listing is seen as a foundation for scaling the company into a regionally integrated, innovation-driven enterprise [5] Business Operations - BioNexus Gene Lab Corp. specializes in RNA-based blood diagnostics and is a leading supplier of industrial chemical raw materials in Southeast Asia [5] - The company is expanding its RNA-based genomic diagnostics business, MRNA Scientific, and driving the adoption of non-invasive blood tests for major diseases [6] - The specialty materials subsidiary, Chemrex, aims to meet the growing demand for high-performance chemical raw materials while focusing on sustainable development [6]